scholarly journals Clinical Impact of Multiplex PCR for Rapid Identification of Staphylococcus aureus Bacteremia in Hospitalized Pediatric Patients

2015 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
Sanet Torres-Torres ◽  
Jennifer Goldman ◽  
Angela Myers ◽  
Dwight Yin ◽  
Rangaraj Selvarangan ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Multiplex Pcr ◽  
Pediatric Patients ◽  
Rapid Identification ◽  
Clinical Impact ◽  
Staphylococcus Aureus Bacteremia

scholarly journals 2559. Incidence and Clinical Impact of Discordant Genotypic and Phenotypic Categorization of Methicillin Susceptibility in Staphylococcus aureus Bacteremia

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S70-S70
Author(s):  
Jessica Gulliver ◽  
Brittney Jung-Hynes ◽  
Derrick Chen
Keyword(s):  
Staphylococcus Aureus ◽  
Blood Culture ◽  
Positive Blood Culture ◽  
Clinical Laboratory ◽  
Laboratory Data ◽  
Rapid Identification ◽  
Clinical Impact ◽  
Staphylococcus Aureus Bacteremia ◽  
Oxacillin Resistance ◽  
Initial Hospitalization

Abstract Background Methicillin-susceptible/methicillin-resistant Staphylococcus aureus (MSSA/MRSA) can be directly identified from positive blood culture bottles using molecular methods. This provides faster results than traditional phenotypic testing, but discrepancies between the two are occasionally found. We sought to determine the incidence and clinical impact of such discrepancies. Methods Positive blood culture bottles are routinely tested in the hospital clinical laboratory for mecA via Xpert MRSA/SA BC (PCR), and antimicrobial susceptibility testing (AST) via MicroScan PC33 is performed on recovered S. aureus isolates; discrepancies between PCR and AST are resolved by repeat and supplemental (Kirby-Bauer) testing. A retrospective review of medical and laboratory data from January 2015 to December 2017 was performed on all patients that had discordant PCR and AST results. Results Approximately 1,200 PCR assays were performed from January 2015 to December 2017, and there were 5 (0.4%) cases with discordant AST Results. Four cases were classified as MSSA by PCR but MRSA by AST, and 1 case was classified as MRSA by PCR but MSSA by AST. For the former group, antimicrobial therapy was changed in 2 patients to cover MRSA and 1 patient was readmitted, while the remaining 2 patients were already being treated for MRSA; for the latter case, this patient was treated for MRSA during the initial hospitalization, but was readmitted with disseminated MSSA and subsequently deceased. Based on genetic targets identified by PCR and cefoxitin and oxacillin AST, discrepancies were likely due to borderline oxacillin resistance (BORSA) (n = 1), presence of an SCCmec variant not detected by PCR (n = 1), or undetermined (n = 3). Conclusion Rapid identification of MRSA bacteremia via PCR provides actionable information to direct empiric treatment. While highly accurate, PCR results are infrequently not corroborated by AST. This rare possibility should be considered when modifying therapy based on initial PCR results, and there should be close communication between the clinical team and laboratory for these challenging cases. Disclosures All authors: No reported disclosures.

Staphylococcus aureus bacteremia after thermal injury: The clinical impact of methicillin resistance

Burns ◽  
2013 ◽  
Vol 39 (3) ◽  
pp. 404-412 ◽  
Author(s):  
Panagiotis Theodorou ◽  
Rolf Lefering ◽  
Walter Perbix ◽  
Timo A. Spanholtz ◽  
Marc Maegele ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Thermal Injury ◽  
Methicillin Resistance ◽  
Clinical Impact ◽  
Staphylococcus Aureus Bacteremia

Staphylococcus Aureus Bacteremia Without a Localizing Source in Pediatric Patients

2014 ◽  
Vol 33 (5) ◽  
pp. e132-e134 ◽  
Author(s):  
John Ligon ◽  
Sheldon L. Kaplan ◽  
Kristina G. Hulten ◽  
Edward O. Mason ◽  
J. Chase McNeil
Keyword(s):  
Staphylococcus Aureus ◽  
Pediatric Patients ◽  
Staphylococcus Aureus Bacteremia

scholarly journals STAPHYLOCOCCUS AUREUS BACTEREMIA IN PEDIATRIC PATIENTS WITH CANCER

2010 ◽  
Vol 29 (2) ◽  
pp. 172-174 ◽  
Author(s):  
Ashok Srinivasan ◽  
Steven Seifried ◽  
Liang Zhu ◽  
Deo K. Srivastava ◽  
Patricia M. Flynn ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Pediatric Patients ◽  
Patients With Cancer ◽  
Staphylococcus Aureus Bacteremia

Pre-clinical impact of the synergistic mechanism of daptomycin and ceftaroline in patients with methicillin-resistant Staphylococcus aureus bacteremia infections

2021 ◽  
Vol 15 ◽  
Author(s):  
Jennyflore Eliazar ◽  
Tevin Johnson ◽  
Christiane Chbib
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Inhibitory Concentration ◽  
Clinical Impact ◽  
In Vitro Studies ◽  
Methicillin Resistant ◽  
Colony Forming Unit ◽  
Staphylococcus Aureus Bacteremia ◽  
Synergistic Mechanism

Background: Our study aims at assessing the pre-clinical impact of the synergistic mechanism of Daptomycin (DAP) and Ceftaroline (CFT) in patients with Methicillin-resistant Staphylococcus aureus bacteremia infections (MRSAB). Methods: A systematic overview was conducted by searching PubMed, Oxford academic, and Cochrane library up to June 2020. Study selection and data extraction: All English- language clinical trials, in vitro studies, and case reports related to the synergistic drug therapy for MRSAB. Results: In the case of MRSAB infections, we examined two different in vitro studies that showed effective synergism with DAP and CFT. The minimum inhibitory concentration (MIC) range observed for each is as follow: DAP 0.125-1 mg/L, CFT 0.38-1 mg/L, DAP + CFT 0.094-0.5 mg/L, vancomycin (VAN) 0.75-2 mg/L, VAN + CFT 0.25-2 mg/L. DAP + CFT combination displayed the most efficacy with the lowest MIC. The statistical analysis performed showed that DAP + CFT obtained significantly lower fractional inhibitory concentration (FIC) values (0.941 ± 0.328) compared with VAN + CFT. In vitro activities of regimens tested on DAP non-susceptibility and VAN intermediate after 96 hours showed DAP 8.29 ± 0.03a log10 CFU/mL, VAN 6.82 ± 0.04a log10 Colony Forming Unit (CFU)/mL, CFT 4.63 ± 0.19a log10 CFU/mL, DAP + CFT 1.15 ± 0.20b log10 CFU/mL, VAN + CFT 3.18 ± 0.49a log10 CFU/mL. ( a meaning significantly different than DAP plus CFT, P< equal to 0.001b meaning therapeutic enhancement combination was defined as ≥ 2 log10 CFU/ml reduction over the most active single agent). Based on these results, although DAP was not susceptible, the colony forming unit (CFU) for DAP and CFT had the best therapeutic results. Conclusion: In vitro studies have shown that combination DAP and CFT is more efficacious than the combination on VAN and CFT in MRSA bacteremia infections. The synergic effects of DAP (bactericidal) and CFT (bactericidal) is statistically significant, in recent trials, warranting promising evidence for its use in complicated bacteremia infection.

Sign in / Sign up

Export Citation Format

Share Document